Connect with us

Cannabis News

Colorado Marijuana Officials Announce Crackdown On Sales Of Hemp Products Amid ‘Risks To Public Safety’

Published

on

These issues “pose serious risks to public safety, market integrity, and the tax revenue framework that supports Colorado’s regulated cannabis industry.”

By Christopher Osher, ProPublica and Evan Wyloge, The Denver Gazette

This story was originally published by ProPublica.

Colorado regulators announced Monday that they plan to crack down on companies that sell cheaper, potentially dangerous, illegal hemp products as marijuana.

The state’s Division of Marijuana Enforcement said it had identified “compliance issues” that threaten to dismantle the marijuana industry in the nation’s first legal retail market.

These problems “pose serious risks to public safety, market integrity and the tax revenue framework that supports Colorado’s regulated cannabis industry,” the agency said in an industry newsletter.

An investigation by the Denver Gazette and ProPublica in January reported that despite Colorado being one of the first states to ban the sale of intoxicating hemp products, the legislature and regulators. he failed adopting many of the rules that other states have used to keep hemp products off the medical marijuana shelves.

Creating evaporative and edible liquid distillate from hemp is much cheaper than using marijuana, giving companies a competitive advantage.

But regulators say they are concerned that manufacturers are relying on toxic and dangerous chemicals to convert the non-toxic CBD compound that is predominant in hemp into THC, the psychoactive compound that makes people feel high. Regulators have banned this chemical synthesis, saying they fear chemical residues could remain in the finished product, putting consumers at risk.

Colorado manufacturers have taken advantage of loopholes in the state’s testing and enforcement system to continue using hemp to make products marketed as marijuana, even though doing so is against state law, according to regulatory studies, previous agency bulletins and testimony and lab results contained in several lawsuits.

In 2024, state investigators found that a popular brand of marijuana sold at dispensaries was not only derived from hemp, but also contaminated with methylene chloride, the chemical often used to convert CBD from hemp into THC. Marijuana is banned by Colorado regulators and banned for most uses by the US Environmental Protection Agency because it can cause liver and lung cancer and damage the nervous, immune and reproductive systems.

Ware House, the company that manufactured these vaporizers, relinquished its marijuana license in response to the investigation. Ware Hause’s owner, Thanh Hau, and the company’s lawyer declined to comment.

Congress passed a law last November that bans nearly all hemp products nationwide starting this fall, but it’s unclear how the government will enforce the ban, and hemp growers are reeling.

In December, President Donald Trump issued an executive order telling his aides to work with Congress to develop rules that could allow certain hemp products.

The Colorado Division of Marijuana Enforcement made the announcement Monday newsletter agency officials stated that they “identified and investigated evidence” that marijuana companies are using illegal practices and prohibited methods to manufacture products, instead of relying on marijuana, which is supposed to be monitored for safety.

The Colorado Hemp Association and the Colorado Hemp Education Association did not immediately respond to requests for comment.

Beyond safety concerns, the bulletin also noted that some marijuana manufacturers and growers are avoiding marijuana tax obligations through “a pattern of non-compliance” in sales operations they report to the state’s “seed-to-sale” tracking system, which tracks marijuana from the initial planting to the sale of flower, vapes and other products at dispensaries.

Companies misrepresent marijuana sales at nominal prices, in some cases as low as $1 per pound for unprocessed marijuana material, the newsletter said. Those products typically fetch more than $600 per pound on the market, depending on the category of marijuana, according to industry experts.

That fraudulent reporting has stolen millions of dollars in marijuana taxes from state and local governments, industry experts say, though no official estimate is available.

The agency said it will follow emergency rules to address these issues. The bulletin emphasized that suspicious and abnormal transactions and inventories detected by the state will prompt investigations. Companies caught using hemp or other illegal material passed off as marijuana face “immediate product embargo, license suspension or revocation, significant fines and law enforcement,” regulators warned.

The Denver Gazette and ProPublica have tried to track the anomalous transactions, but the Division of Marijuana Enforcement’s sales transaction records, even those that do not identify the companies, are not public.

Marijuana industry representatives met with the division’s regulators late last month to push for a more aggressive response to the agency’s hemp replacement, even though it could affect some companies in the industry. The representatives argued that bad actors are unfairly driving down prices and shifting the tax burden to manufacturers and growers who are trying to comply with the rules. The newsletter was released a couple of weeks after that meeting.

“The division is also considering additional changes to its testing and screening protocols” to detect illegal products and prohibited methods, and may require additional laboratory tests “if needed for products throughout the supply chain,” the agency’s bulletin said.

This article was produced in partnership with ProPublica’s Local Reporting Network Denver Magazine. Sign up for Submissions to receive stories in your inbox every week.

user photo WeedPornDaily.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis News

State hemp license applications end April 30

Published

on

By











Those wishing to grow and process hemp this year must apply for a license from the Minnesota Department of Agriculture (MDA) by April 30. Each license is valid until December 31 of the year it is issued. Graduates must reapply annually to continue in the program. An MDA license is required for individuals and businesses.

So far, about 30 people have applied for the 2026 MDA license, compared to 84 applicants last year.

These licenses are for the cultivation and processing of industrial hemp only. The hemp license application is not for adult use or for growing or selling medical cannabis. The application is also not intended for the sale of hemp-derived cannabinoid products. Information on adult use and medical cannabis is available Office of Cannabis Management (OCM) website.

There are applications of industrial hemp MDA website. Along with the online form, first-time applicants and authorized representatives must submit fingerprints and pass a criminal background check.

There are also several updates for the 2026 season. The extraction of cannabinoids from hemp is now regulated by the OCM, meaning that anyone interested in this type of processing will need a separate licence. The rates have also changed. The base cost of a hemp license is now $400, with an additional $250 per growing or processing location. The previous $250 processor license fee has been removed, but a 5% surcharge now applies to upgrades to MDA’s technology systems.

All authorized representatives listed on an application must pass a background check before being licensed. In addition, each lot of hemp must undergo THC testing before harvest, and each official sample collected by the MDA costs $100.

Source: Minnesota Department of Agriculture










Continue Reading

Cannabis News

Nascent medical cannabis industry aims for growth

Published

on

By











The medicinal cannabis sector is struggling to take root, and another specialist processing plant is set to close. But with current regulations and a new collective industry in mind, New Zealanders are promising to reduce their reliance on imported medicinals.

There was great excitement when medicinal cannabis was legalized and then regulated in 2020, with the hope of growing the domestic sector and serving patients here and abroad. However, since then, several companies have closed their doors, including Greenfern Industries, Cannasouth and, most recently, Helius Therapeutics.

The latter plans to close the East Tāmaki plant, affecting 65 workers. It is one of the few medicinal cannabis factories in the entire nation that has a specialized processing certificate called “Good Manufacturing Practice” (GMP).

Medical Cannabis Council executive director Sally King said that under current rules, most growers did not have such certification, and could only sell raw ingredients, not processed products such as more profitable cannabis capsules.

Read more at the town










Continue Reading

Cannabis News

Medical Marijuana Helps People Stop Using Opioids, Sleeping Aids And Other Prescription Drugs, Study Shows

Published

on

By

Using medical marijuana appears to help reduce the use of other medications, including opioids, sleep aids and antidepressants, according to a new study of more than 3,500 patients. They experience far fewer negative side effects after switching from prescription drugs to cannabis.

The survey results show that across all medication categories, patients were able to reduce their use of other prescription drugs by an average of 84.5 percent after starting to use medical cannabis.

More than half of the patients (58.9 percent) completely stopped using other prescription drugs.

The study, conducted and published by medical cannabis and telehealth company Bloomwell, conducted an online survey of 3,528 patients in Germany last month.

“Through the use of medical cannabis, patients were able to reduce their use of other prescription medications by an average of 84.5% across all categories.”

93.4 percent of patients taking sleeping pills were able to cut their use in half after starting medical marijuana, and 75.5 percent were able to get off the medication completely.

For methylphenidate, an ADHD drug sold under the name Ritalin, 77.3 percent of medical marijuana patients stopped completely.

61 percent of patients who were previously dependent on opioids were able to stop completely with the help of medical marijuana.

Stopping the use of prescription drugs led to a significant reduction in drug-related side effects, with 60.7 percent reporting no longer experiencing them.

“These patient reports demonstrate that in many cases, in addition to the treatment of the actual symptoms, one of the key reasons for an individual therapeutic trial with medical cannabis is the absence or reduction of medication-related side effects,” the study concluded.

“60.7% of patients reported no longer experiencing medication-related side effects from using medical cannabis.”

There were positive side effects, however, with 67.8 percent saying medical cannabis helped them concentrate better, 61.9 percent said it helped them foster more social relationships, and 53.9 percent experienced fewer sick days from work.

“The primary reason for prescribing medicinal cannabis, in addition to treating symptoms, is to reduce or avoid the side effects of other medications,” Julian Wichmann, Bloomwell’s founder and CEO, said in a press release. “For example, anyone who can completely stop opioids using medical cannabis has a good chance of going about their daily lives and working without side effects.”

“So we shouldn’t demand restrictions on access to medical cannabis, but rather make sure doctors are willing to do an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to their colleagues,” he said. “At the same time, our survey shows that we should finally discuss the great benefits of medical cannabis more openly, instead of only warning about the empirically unproven risks and discrediting the flower.”

This is not the first study to position medical cannabis as a safer alternative to opioids and other prescription drugs.

About One in three Americans who use CBD say they take it as an alternative or supplement to at least one medication—especially painful ones—according to a federally funded study published in February.

Also, a recent federally funded study, published by the American Medical Association (AMA), added further evidence Marijuana can be an effective substitute for opioids in the treatment of chronic pain.

Other studies published by the AMA have found legalizing marijuana for medical or recreational purposes “Significantly associated with reduced opioid use among patients diagnosed with cancer.”

A separate paper published in October also found that Legalizing medical marijuana “is associated with a significant reduction in opioid prescriptions.”

In August, however, Australian researchers published a study that shows this Marijuana can be an effective substitute for opioids in pain management treatment.

Another study published last year in the journal Drug and Alcohol Review found that daily drug users with chronic pain cannabis use was associated with greater likelihood of opioid cessation-Especially among men.

Other studies also found this legalizing medical cannabis appears to have significantly reduced payments to doctors from opioid manufacturers who specialize in pain, the authors found that “this reduction is a consequence of the availability of medical marijuana as a substitute” for prescription analgesics.

Other recent studies also showed a decline in fatal opioid overdoses in jurisdictions where marijuana was legalized for adults. That research found a ‘consistent negative relationship’ between legalization and fatal overdoses, effects more pronounced in states that legalized cannabis earlier in the opioid crisis. The authors estimated that legalizing recreational marijuana “is associated with a decrease of 3.5 deaths per 100,000 people.”

“Our findings suggest that expanding access to recreational marijuana could help combat the opioid epidemic,” the report said. “Prior studies overwhelmingly indicate that marijuana (especially for medical use) can reduce opioid prescriptions, and we see it successfully reducing overdose deaths as well.”

Another recently published report on prescription opioid use in Utah follows the state legalizing medical marijuana found that the availability of legal cannabis reduced opioid use among chronic pain patients and helped reduce prescription drug overdose deaths across the state. Overall, the study’s results indicated that “cannabis plays a significant role in pain management and reducing opioid use,” he said.

President Donald Trump said in December that marijuana can “make people feel a lot better.” and serves as a “substitute for addictive and potentially deadly opioid painkillers.” issued an executive order to federally regulate cannabis and promote access to CBD for therapeutic purposes. He clarified, however, that he personally has no interest in using marijuana himself.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media